Market capitalization | $1.94b |
Enterprise Value | $2.03b |
P/E (TTM) P/E ratio | 99.86 |
EV/FCF (TTM) EV/FCF | 71.19 |
EV/Sales (TTM) EV/Sales | 7.60 |
P/S ratio (TTM) P/S ratio | 7.25 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 51.35% |
Revenue (TTM) Revenue | $267.20m |
As a Free StocksGuide user, you can view scores for all 6,892 stocks worldwide.
6 Analysts have issued a MannKind Corporation forecast:
6 Analysts have issued a MannKind Corporation forecast:
Sep '24 |
+/-
%
|
||
Revenue | 267 267 |
51%
51%
|
|
Gross Profit | 192 192 |
66%
66%
|
|
EBITDA | 65 65 |
1,827%
1,827%
|
EBIT (Operating Income) EBIT | 57 57 |
712%
712%
|
Net Profit | 22 22 |
169%
169%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
MannKind Corp. is a biopharmaceutical company. It focuses on the discovery, development and, commercialization of therapeutic products for diseases, such as diabetes and cancer. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Westlake Village, CA.
Head office | United States |
CEO | Michael Castagna |
Employees | 414 |
Founded | 1991 |
Website | www.mannkindcorp.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.